<DOC>
	<DOCNO>NCT01093521</DOCNO>
	<brief_summary>The purpose research study test pharmacokinetics , safety , tolerability intravenous infusion drug call Ganite ( gallium nitrate ) patient cystic fibrosis . We want see drug safe tolerable see high level drug find sputum . Funding Source - Food Drug Administration ( FDA ) Office Orphan Products Development ( OOPD )</brief_summary>
	<brief_title>A Pharmacokinetic Safety Study IV Gallium Nitrate ( Ganite ) Cystic Fibrosis Patients</brief_title>
	<detailed_description>This two center pharmacokinetic safety dose study IV gallium nitrate ( Ganite® ) cystic fibrosis ( CF ) patient . Eighteen subject plan . Each subject administer single 5-day infusion study medication ( one 2 dos ) . No placebo use . Each subject receive 5 day continuous infusion experimental treatment . There two dosing cohort ( cohort 1 : 100 mg/m2/day cohort 2 : 200 mg/m2/day ) . Cohort 2 begin enrollment Data Safety Monitoring Committee ( DSMC ) safety review approval cohort 1 data . Study visit occur baseline ( day 1 ) , day 3 ( visit 2 ) , day 6 ( visit 3 ) , day 8 ( visit 4 ) , day 14 ( visit 5 ) , day 28 ( visit 6 ) , day 56 ( visit 7 ) . Screening data review determine subject eligibility . Subjects meet inclusion criterion none exclusion criterion enter study . The following treatment regimen use : • Experimental treatment continuous infusion gallium nitrate follow dos cohort 1 : 100 mg/m2/day cohort 2 : 200 mg/m2/day All subject receive least one dose study medication consider evaluable safety efficacy analysis . Incidence adverse event monitor trial . Primary endpoint assessment pharmacokinetic safety/tolerability data . Secondary efficacy assessment base change lung function sputum P. aeruginosa density sputum . Total duration subject participation five week . Total duration study expect 20 month .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Gallium nitrate</mesh_term>
	<criteria>1 . Adult male female , 18 55 year age 2 . Documented chronic colonization Pseudomonas Aeruginosa ( Pa ) 3 . Confirmed diagnosis CF : 1 . Documented history &gt; 60 mmol/L chloride concentration pilocarpine sweat chloride test And/Or 2 . Genotype two identifiable mutation consistent CF , accompany one phenotypic feature consistent diagnosis CF 4 . Forced expiratory volume first second ( FEV1 ) ≥ 30 % predict value 5 . Able expectorate sputum 6 . Serum liver function test ≤ 2.5 x upper limit normal 7 . Serum urea nitrogen ( BUN ) creatinine ≤ 1.5 x upper limit normal 8 . Serum creatinine ≤ 2.0 mg/dl 9 . Hemoglobin ≥ 9 g/dl , platelet ≥ 100,000/mm3 , white blood cell ( WBC ) ≥ 4,500/mm3 ≤ 15,000/mm3 10 . Ionized calcium ≥ low limit normal 11 . Able understand sign inform consent document , communicate Investigator , comply requirement protocol 12 . If female childbearing potential , must negative pregnancy test Day 1 prior receive study drug 13 . If female childbearing potential , willing use adequate contraception , determine investigator , duration study 1 . Acute pulmonary exacerbation require antibiotic intervention within 2 week prior screen 2 . Osteoporosis define recent dexa scan within prior 5 year Tscore ≤ 2.5 3 . Pregnant lactate female 4 . Known sensitivity gallium 5 . Use biphosphonates 6 . Use investigational drug and/or participate clinical trial within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>IV Gallium</keyword>
	<keyword>Gallium</keyword>
	<keyword>Ganite</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Gallium Infusion</keyword>
</DOC>